Tesaglitazar

IDrugs. 2005 Nov;8(11):927-35.

Abstract

AstraZeneca plc is developing tesaglitazar, an oral dual peroxisome proliferator-activated receptor alpha/gamma agonist, for the potential improvement of dyslipidemia and glycemic control in type 2 diabetic patients.

MeSH terms

  • Alkanesulfonates / chemical synthesis
  • Alkanesulfonates / metabolism
  • Alkanesulfonates / pharmacology
  • Alkanesulfonates / therapeutic use*
  • Animals
  • Clinical Trials as Topic
  • Humans
  • PPAR alpha / agonists*
  • PPAR gamma / agonists*
  • Patents as Topic
  • Phenylpropionates / chemical synthesis
  • Phenylpropionates / metabolism
  • Phenylpropionates / pharmacology
  • Phenylpropionates / therapeutic use*
  • Structure-Activity Relationship

Substances

  • Alkanesulfonates
  • PPAR alpha
  • PPAR gamma
  • Phenylpropionates
  • tesaglitazar